| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Technology evaluation |
a Beth Israel-Deaconess Medical Center, Boston, MA
b RSA Laboratories, Bedford, MA
c Johns Hopkins University, Baltimore, MD
* Correspondence and reprints: John Halamka, MD, 1135 Tremont, Boston, MA 02120. (Email: jhalamka{at}caregroup.harvard.edu).
Received for publication: 05/10/06; accepted for publication: 08/07/06.
The VeriChipTM is a Radio-Frequency Identification (RFID) tag produced commercially for implantation in human beings. Its proposed uses include identification of medical patients, physical access control, contactless retail payment, and even the tracing of kidnapping victims.As the authors explain, the VeriChip is vulnerable to simple, over-the-air spoofing attacks. In particular, an attacker capable of scanning a VeriChip, eavesdropping on its signal, or simply learning its serial number can create a spoof device whose radio appearance is indistinguishable from the original. We explore the practical implications of this security vulnerability. The authors argue that:
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |